Gadolinium deposition in the brain of patients with relapsing-remitting multiple sclerosis after 10 years of follow-up

Background/Aim.Since 2014 and the publication of results first study on accumulation gadolinium contrast, we have witnessed a growing body evidence deposition retention in brain after use gadolinium-based contrast agents (GBCAs). However, there is still no strong clinical adverse effects GBCAs brain. The aim was to determine existence deposits patients with realpsing-remiting (RR) multiple sclerosis (MS), 10-year follow-up period. During this period regularly,each year, undergone magnetic resonance imaging (MRI) administration (gadopentetate dimeglumine - Magnevist?) order follow course disease. Methods. A cohort 20 formed for study. ratio values signal intensity (SI) different regions brain-to- cerebrospinal fluid (CSF) compared , each patient, initial MRI examination, examination 10 years later . Results. Frontal cortex -to-CSF (p<0.01), occipital cortex-to-CSF (p <0.01), white matter radial corona-to-CSF parietal <0.05), thalamus-to-CSF = 0.051), putamen-to-CSF =0.06), anterior posterior limb capsula interna (p=0.062) SI ratios increased gadopentetate administrations. Conclusion. In statistically significant increase pre-contrast T1W sequence following structures: frontal, parietal, cortex, as well supratentorial matter. An absolute ? registered frontal cerebellar hemispheres. Slightly less, but more than 55-65% structures putamen, cornu capsule interna, corpus callosum (CC) splenium, pons, thalamus, nucleus caudatus (NC), substantia nigra (SN), CC genu temporal cortex.This result speaks favor chronic agent dimeglumine, structures.